Methods: Electronic medical records (EMR) identified 1457 HIV patients from the HIV clinic at Henry Ford Hospital, Detroit, Michigan from March, 2013 to November, 2015. Race/ethnicity and gender were identified by self-report and then a retrospective EMR review of patients tested for, and documented ICD-9 codes for dyslipidemia was done. Descriptive analyses and group comparisons were performed between AA and other racial/ethnic groups.
Results: 1220 HIV patients had lipid levels tested with 25.7% having dyslipidemia after HIV diagnosis. Among those, it was found that lipid abnormalities varied by race; on average, Hispanics, had lower total cholesterol (p-value 0.040), AA patients had lower triglycerides (p-value <0.001), and White patients had higher triglycerides (p-value >0.001). HDL levels were higher in AA patients and lowest in White patients (p-value <0.001), while Hispanics had lower LDL values (p-value 0.009). There was no statistically significant (p-value 0.519) difference between the lipid lowering drug (LLD) group prescribed by race, and the type of dyslipidemia was the primary predictor of LLD provided to the patients (p-values <0.001). Patients prescribed fibrates were statistically more likely to have met their ATP III treatment goals at 1 year as compared to statins, regardless of race (p-value 0.005). The odds of meeting treatment goals were 54% (OR 0.46, CI 0.26-0.71) less among AA patients regardless of medication.
Conclusion: Dyslipidemia is prevalent in our HIV population. Racial differences in testing, lipid abnormalities and treatment outcomes among these vulnerable HIV minorities necessitate further investigation to close the gaps in care and improve our management of dyslipidemia for our HIV patients.
J. Mckinnon, None
See more of: Poster Abstract Session